This study is testing a new oral medication called BGE-102 in adults who have obesity and risk factors for heart disease. The main goal is to see how BGE-102 affects inflammation in the body, measured by a blood test called hsCRP. Researchers believe that BGE-102 might help improve obesity and heart health by reducing inflammation. You would receive either BGE-102 or a placebo (an inactive capsule that looks like the study drug). The study will also check how safe BGE-102 is and if people can tolerate it well. To join, you need to be an adult with a BMI between 32-42 kg/m², have high hsCRP levels, and at least one heart disease risk factor or feature of metabolic syndrome. The study is currently recruiting participants.

Study design

This is a Phase 2 interventional study with 160 planned participants. Participants will be randomly assigned to receive one of three doses of BGE-102 or a placebo.

What's involved

The study lasts about 20 weeks, with 12 weeks of treatment. You would have visits every 2 weeks for the first month of treatment, then every 4 weeks until week 16.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 4 weeks after the 12-week treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.